Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Plasmablastic Lymphoma 1Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Hodgkin Disease 1HIV Infections 1Glioblastoma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 83Cyclophosphamide 55Specimen Handling 54Carboplatin 53fludarabine 44Nivolumab 43Magnetic Resonance Spectroscopy 43Gemcitabine 41Biopsy 40venetoclax 33Bevacizumab 33Dexamethasone 31Paclitaxel 29Pemetrexed 27Injections 27Cisplatin 27Docetaxel 26Azacitidine 22atezolizumab 21Rituximab 21Oxaliplatin 21Capecitabine 21Lenalidomide 20Ipilimumab 20Temozolomide 19Fulvestrant 19Cetuximab 19abemaciclib 18Fluorouracil 18Cytarabine 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Carmustine × 90 days × Clear all
NCT02797470 2026-05-18

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

AIDS Malignancy Consortium

Phase 1/2 Active not recruiting
11 enrolled 9 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, T-Cell, Lymphoma, Mantle-Cell

NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

VBI Vaccines Inc.

Phase 1/2 Terminated
70 enrolled
CNS

Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡